AR091236A1 - Compuestos de tetrahidropirazolopirimidina - Google Patents
Compuestos de tetrahidropirazolopirimidinaInfo
- Publication number
- AR091236A1 AR091236A1 ARP130101930A AR091236A1 AR 091236 A1 AR091236 A1 AR 091236A1 AR P130101930 A ARP130101930 A AR P130101930A AR 091236 A1 AR091236 A1 AR 091236A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- formula
- och3
- nitrogen
- atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 24
- -1 1,4-dimethylthiazolyl Chemical group 0.000 abstract 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 16
- 229910052757 nitrogen Inorganic materials 0.000 abstract 14
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 abstract 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 6
- 125000004193 piperazinyl group Chemical group 0.000 abstract 6
- 125000003386 piperidinyl group Chemical group 0.000 abstract 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- 150000001555 benzenes Chemical class 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 3
- 150000003222 pyridines Chemical class 0.000 abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 150000002461 imidazolidines Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 150000003854 isothiazoles Chemical class 0.000 abstract 1
- 125000006384 methylpyridyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003218 pyrazolidines Chemical class 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003233 pyrroles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal farmacéuticamente aceptable del mismo, o un estereoisómero del mismo o mezcla de estereoisómeros del mismo, donde R¹ es piperidinilo opcionalmente sustituido, piridilo opcionalmente sustituido, pirrolilo opcionalmente sustituido, pirroldinilo opcionalmente sustituido, 1,4-dimetiltiazolilo, 2-etil-4-metiltiazolilo, 2-isopropiltiazol-5-ilo, tiazolilo, 3-etiltiazol-5-ilo, 1-metilsulfonilpiperidin-4-ilo, o R¹ es -C(O)Z, donde Z es piperazinilo, (S)-2-(3-etilpiperazin-1-ilo), pirrolopirrolilo opcionalmente sustituido, piperidin-3-ilamino, o, R¹ es un resto de fórmula (2), donde R¹³ es H, metilpirazolilo, metilimidazolilo, bencilo, 3-hidroxibutilo, 3-(dimetilamino)-2,2-dimetilpropilo, etilamida, metilpiridilo, metilsulfonilo, (1-metilimidazol-2-il)metilo, (1,5-dimetilimidazol-4-il)metilo, (1-metilpirrol-2-il)metilo, o donde R¹³ es C(O)W, donde W es -N(CH₃)₂, piperidinilo, piperazinilo, o morfolinilo, o, R¹ es un resto de fórmula (3), donde R¹⁴ es -C(O)CH₃, H, o (1-metilpirrol-2-il)metilo, o, R¹ es un resto seleccionado del grupo de fórmulas (4), o R¹ es un compuesto de fórmula (5) donde A, B, y D pueden ser todos carbonos, o donde dos de A, B, y D son carbono y el otro es nitrógeno, o donde uno de A, B, y D es carbono y los restantes dos son nitrógeno; y cuando A es nitrógeno R⁴ se encuentra ausente, cuando B es nitrógeno R² se encuentra ausente y cuando D es nitrógeno R³ se encuentra ausente; y donde R² es H, -CH₃, o F, o, con R³ y los átomos en las posiciones a y b, forma una piridina opcionalmente sustituida o un pirazol; y donde R³ es H, F, Cl, -CN, -CH₃, -OCH₃, -OH, -NH₂, metilsulfonilo, o un resto del grupo de fórmulas (6), o, con R⁴ y los átomos en las posiciones b y c, forma un benceno opcionalmente sustituido, imidazol opcionalmente sustituido, pirazol opcionalmente sustituido, pirazolidina opcionalmente sustituida, imidazolidina opcionalmente sustituida, isotiazol opcionalmente sustituido, un resto de fórmula (7) o, con R² y los átomos en las posiciones a y b, forma una piridina opcionalmente sustituida o pirazol opcionalmente sustituido; y donde R⁴ es F, -CN, -OCH₃, -OEt, H, Cl, Br, -NH-C(O)-CH-(CH₃)₂, -N(CH₃)₂, -CH₃, -CH₂OH, un resto de fórmula (8), (9) ó (10), piperazinilo opcionalmente sustituido, 4-hidroxipiperizin-1-ilo, piperidinilo opcionalmente sustituido no unido a un grupo fenilo a través de un nitrógeno, o, con R³ y los átomos en las posiciones b y c, forma un anillo pirazol opcionalmente sustituido o el resto de fórmula (7), o, con R⁵ y los átomos en las posiciones c y d, forma un anillo pirazol opcionalmente sustituido o un anillo pirrol opcionalmente sustituido, o, R⁴ es -(q)-C(O)X, donde q es una unión, es -NH-, o es -CH₂-, y donde X es -NR¹¹R¹², donde R¹¹ y R¹² son ambos H, ambos -CH₂CH₃, o ambos -CH₃, o donde uno de R¹¹ y R¹² es H y el otro es 1,1-dimetiletilo, ciclobutilo, ciclopropilo, alquilo inferior, alcohol metílico, alcohol propílico, ciclobutilmetilo; 2,3-dihidroxipropilo, bencilo, azetidinilo, pirrolidinilo, piperidinilo, metilazetidinilo, -CH₂-NH-CH₃, pirazolilo, piperazinilo, alcohol, -OCH₃, o un resto de fórmula (11), o donde X es pirrolidinilo opcionalmente sustituido unido a través de un nitrógeno al grupo carbonilo de R⁴, piperidinilo opcionalmente sustituido no unido a través de un nitrógeno al grupo carbonilo de R⁴, pirrolidinilo opcionalmente sustituido unido a través de un nitrógeno al grupo carbonilo de R⁴, piperazinilo opcionalmente sustituido unido a través de un nitrógeno al grupo carbonilo de R⁴, o morfolinilo opcionalmente sustituido unido a través de un nitrógeno al grupo carbonilo de R⁴, o un compuesto seleccionado del grupo de fórmulas (12); y donde R⁵ es H, F, Cl, -CH₃, -OCH₃, pirrolilo, -CH₂OH, -NH₂, -OH, un resto de fórmula (13), o de fórmula (14), o, con R⁴ y los átomos en las posiciones c y d, forma un benceno opcionalmente sustituido, un pirazol opcionalmente sustituido, o un pirrol opcionalmente sustituido, o, con R⁶ y los átomos en las posiciones d y e, forma una piridina opcionalmente sustituida, o R⁵ es C(O)Y, donde Y es -NH₂, -N(CH₃)₂, piperazinilo opcionalmente sustituido, piperidinilo opcionalmente sustituido, o un resto del grupo de fórmulas (15); y donde R⁶ es H, F, -CH₃, -CF₃, o, con R⁵ y los átomos en las posiciones c y d, forma un benceno opcionalmente sustituido o un pirazol opcionalmente sustituido; y donde R⁷ es -CF₃ o -CHF₂; y donde R⁸ es un resto de fórmula (16) ó (17); y donde R⁹ es Br, Cl, F, l, o H; con las siguientes condiciones: cuando R⁴ es F: R² no es -CH₃ o F; R³ no es -CH₃, -CN, F, Cl, o -OCH₃; R⁵ no es -CH₃, F, Cl, o -OCH₃; y R⁶ no es -CH₃ o F; cuando R⁴ es Cl: R² no es F; R³ no es F o -CN; R⁵ no es F, -CN, o -C(O)N(CH₃)₂; R⁶ no es -CF₃ o F; D no es nitrógeno; y o bien R⁵ es -C(O)NH₂ o uno de R², R³, R⁵, y R⁶ es -CH₃; cuando R⁴ es -CH₃: R³ no es F; R⁵ no es F; y R⁵ y R⁶ no forman una pirimidina junto con los átomos en las posiciones d y e; cuando R⁴ es -OCH₃: R² no es F; R³ no es Cl o -OCH₃, R⁵ no es Cl o -OCH₃; y R⁶ no es F o -CF₃; cuando R⁴ es -CN: R² no es F; R³ no es Cl, F, o -OCH₃, R⁵ no es Cl, F, o -OCH₃; y R⁶ no es F; cuando R⁴ es -OCH₂CH₃: R³ no es Cl o F; R⁵ no es Cl o F; y R⁶ no es -CF₃; cuando R⁴ es un resto de fórmula (18): R³ no es H o F; y R⁵ no es H o F; cuando R⁴ es el resto de fórmula (18): al menos uno de R², R³, R⁵, y R⁶ no es H; cuando R⁴ es un compuesto de fórmula (19): R³ no es F; y R⁵ no es F; cuando R² es F: R³ no es -OCH₃ o F; R⁵ no es -CN; y al menos uno de R³, R⁴, R⁵, y R⁶ no es H; cuando R² es Cl: R³ no es F; cuando R² es -CH₃: R³ no es Cl; al menos uno de R³, R⁴, R⁵, y R⁶ no es -CH₃; y R⁴ y R⁵ no forman un pirazolilo con los átomos en las posiciones c y d; cuando R³ es -OCH₃: R² no es F; y R⁶ no es F; cuando R³ es F: R² no es -OCH₃; y X no es un resto de fórmula (20); cuando R³ es Cl; R⁵ no es Cl; R¹¹, no es bencilo; y R¹² no es bencilo; cuando R⁵ es Cl, R⁶ no es -CH₃; R¹¹ no es bencilo; y R¹² no es bencilo; cuando R⁵ es F o -OCH₃: R⁶ no es F; cuando R⁶ es F: al menos uno de R², R³, R⁴, y R⁵ no es H; cuando R³ y R⁵ son H: R¹¹ no es ciclopropilo; y R¹² no es ciclopropilo; cuando R⁹ es Cl, R¹ no es un grupo amida; cuando B es nitrógeno y A y D son carbono: R⁴ no puede ser -CN o el resto de fórmula (21); cuando R⁷ es -CHF₂ y R⁴ es un resto de fórmula (22), luego R⁴ no tiene la estereoquímica absoluta de fórmula (23); y donde, cuando R⁸ es el compuesto de fórmula (17) entonces se aplican las siguientes condiciones: cuando R⁴ es F; al menos uno de R², R³, R⁵, y R⁶ no es H; R³ no es C(O)N(CH₃)₂; y R⁵ no es C(O)N(CH₃)₂; cuando R⁴ es Cl: al menos uno de R², R³, R⁵, y R⁶ no es H; cuando R³ es F: R⁴ no es C(O)NHCH₂CH₂CH₂CH₃, C(O)N(CH₃)₂, C(O)NHCH₂CH₂CH₃, o C(O)NHC(CH₃)₃; R⁴ no es C(O)NHCH₂CH₂CH₂OH, C(O)NHCH(CH₃)₂, -CN, o el resto de fórmula (24); R¹ no es un compuesto de fórmula (25) ó (26); R⁵ no es el resto de fórmula (27); R³ no es el resto de fórmula (28); cuando R² es F: R⁵ no es -C(O)NH₂; cuando R² es -CH₃, R⁴ y R⁵ no forman un pirazol con los átomos en las posiciones c y d; y cuando B es nitrógeno, R³ y R⁴ no forman un imidazol opcionalmente sustituido con los átomos en las posiciones b y c; y donde, cuando R⁸ es el compuesto de fórmula (29), entonces se aplican las siguientes condiciones: R⁴ no es -CH₃, -C(O)NHCH₂CH₂OH, -NHC(O)CH(CH₃)₂, o un resto de fórmula (30); cuando R⁴ es C(O)NHCH₃, al menos uno de R², R³, R⁵, y R⁶ no es H; cuando R⁴ es -OCH₃: R³ no es F o -CH₃ y R⁵ no es F o -CH₃; cuando R⁴ es el compuesto de fórmula (31): R³ no es Cl; y R⁵ no es Cl; cuando R⁴ es -C(O)NHCH(CH₃)₂ o -C(O)N(CH₂CH₃)₂: al menos uno de R³ y R⁵ no es H; R⁵ no es -C(O)NH₂; y R⁶ no es -CF₃.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654023P | 2012-05-31 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091236A1 true AR091236A1 (es) | 2015-01-21 |
Family
ID=48626649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101930 AR091236A1 (es) | 2012-05-31 | 2013-05-31 | Compuestos de tetrahidropirazolopirimidina |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9126999B2 (es) |
| EP (1) | EP2855476B1 (es) |
| JP (2) | JP6285918B2 (es) |
| KR (2) | KR102268155B1 (es) |
| CN (2) | CN104507939B (es) |
| AR (1) | AR091236A1 (es) |
| AU (2) | AU2013267204B8 (es) |
| BR (1) | BR112014030060B1 (es) |
| CA (1) | CA2874445C (es) |
| CL (1) | CL2014003278A1 (es) |
| CY (1) | CY1122692T1 (es) |
| DK (1) | DK2855476T3 (es) |
| ES (1) | ES2709119T3 (es) |
| HR (1) | HRP20181889T1 (es) |
| HU (1) | HUE040562T2 (es) |
| IL (2) | IL268013B2 (es) |
| JO (1) | JO3407B1 (es) |
| LT (1) | LT2855476T (es) |
| MX (1) | MX368455B (es) |
| MY (1) | MY172926A (es) |
| NZ (1) | NZ703459A (es) |
| PE (2) | PE20150220A1 (es) |
| PH (2) | PH12014502660B1 (es) |
| PL (1) | PL2855476T3 (es) |
| PT (1) | PT2855476T (es) |
| RS (1) | RS57977B1 (es) |
| RU (2) | RU2733959C2 (es) |
| SG (1) | SG11201407890VA (es) |
| SI (1) | SI2855476T1 (es) |
| SM (1) | SMT201800626T1 (es) |
| TW (1) | TWI572606B (es) |
| UA (1) | UA113440C2 (es) |
| WO (1) | WO2013181579A2 (es) |
| ZA (1) | ZA201409273B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| JP6223563B2 (ja) | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| RU2671496C2 (ru) | 2013-10-14 | 2018-11-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные 5-пиперидин-8-цианохинолина |
| JP2016540013A (ja) * | 2013-12-13 | 2016-12-22 | 武田薬品工業株式会社 | Ｔｌｒ阻害剤としてのピロロ［３，２−ｃ］ピリジン誘導体 |
| CN106132967B (zh) * | 2014-03-27 | 2019-05-28 | 詹森药业有限公司 | 作为ros1抑制剂的化合物 |
| US10414733B2 (en) | 2014-07-31 | 2019-09-17 | Basf Se | Process for preparing pyrazoles |
| US9938100B2 (en) | 2014-12-30 | 2018-04-10 | Kodak Alaris Inc. | System and method for metallic object detection in a media transport system |
| WO2016180833A1 (en) | 2015-05-11 | 2016-11-17 | Basf Se | Process for preparing 4-amino-pyridazines |
| WO2017004734A1 (zh) * | 2015-07-03 | 2017-01-12 | 中国农业大学 | 苄基腙类化合物及其制备方法与应用 |
| EP3411360B1 (en) * | 2016-02-02 | 2020-03-11 | Basf Se | Catalytic hydrogenation process for preparing pyrazoles |
| CN107174585A (zh) * | 2016-03-10 | 2017-09-19 | 兰州大学 | 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| ES2863474T3 (es) * | 2016-07-30 | 2021-10-11 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con dimetoxifenilo como inhibidores de TLR7, TLR8 o TLR9 |
| WO2018024644A1 (en) * | 2016-08-02 | 2018-02-08 | Solvay Sa | Manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives, hydrazinyl compounds and their use |
| EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
| CA3031585A1 (en) * | 2016-09-09 | 2018-03-15 | Novartis Ag | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| CN110177793B (zh) * | 2017-05-18 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | 杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用 |
| ES2921020T3 (es) | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| KR102651947B1 (ko) | 2017-08-04 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물 |
| WO2019099336A1 (en) | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
| KR102037494B1 (ko) | 2017-12-11 | 2019-10-28 | 씨제이헬스케어 주식회사 | 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법 |
| JP7287964B2 (ja) * | 2017-12-15 | 2023-06-06 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドールエーテル化合物 |
| MX2020006168A (es) | 2017-12-18 | 2020-08-13 | Bristol Myers Squibb Co | Compuestos de 4-azaindol. |
| EP3728253B1 (en) * | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| SG11202005696YA (en) * | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole compounds useful as tlr inhibitors |
| SG11202005700SA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Amide substituted indole compounds useful as tlr inhibitors |
| MX2020006014A (es) * | 2017-12-20 | 2020-08-17 | Bristol Myers Squibb Co | Compuestos de diazaindol. |
| SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| ES2965182T3 (es) | 2017-12-20 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con arilo y heteroarilo |
| WO2019122164A1 (en) * | 2017-12-22 | 2019-06-27 | Solvay Sa | Process for the manufacture of pyrazole carboxylic derivatives and precursors thereof |
| JP2021507889A (ja) | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| JP7312745B2 (ja) * | 2018-06-07 | 2023-07-21 | 第一三共株式会社 | アゼチジン誘導体及びそのプロドラッグ |
| US12252484B2 (en) | 2018-09-06 | 2025-03-18 | Hoffmann-La Roche Inc. | Pyrazolopyridine compounds for the treatment of autoimmune disease |
| KR102911861B1 (ko) | 2018-10-24 | 2026-01-12 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 이량체 화합물 |
| CN112955450A (zh) | 2018-10-24 | 2021-06-11 | 百时美施贵宝公司 | 经取代的吲哚和吲唑化合物 |
| EP3877388B1 (en) * | 2018-11-09 | 2023-07-26 | F. Hoffmann-La Roche AG | 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus |
| CA3129178A1 (en) | 2019-02-07 | 2020-08-13 | Beigene, Ltd. | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist |
| ES2987832T3 (es) | 2019-05-09 | 2024-11-18 | Bristol Myers Squibb Co | Compuestos de benzimidazolona sustituidos |
| EP4008720A4 (en) * | 2019-08-02 | 2023-08-02 | BeiGene, Ltd. | IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST |
| US12448395B2 (en) | 2019-10-01 | 2025-10-21 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| WO2021067657A1 (en) | 2019-10-04 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| KR20190120112A (ko) | 2019-10-08 | 2019-10-23 | 씨제이헬스케어 주식회사 | 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법 |
| CN114599652B (zh) | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| WO2021112251A1 (ja) * | 2019-12-06 | 2021-06-10 | 第一三共株式会社 | アゼチジンスルホンアミド化合物 |
| PE20240919A1 (es) | 2021-04-16 | 2024-04-30 | Gilead Sciences Inc | Compuestos de tienopirrol |
| GB202107932D0 (en) * | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3116230B2 (ja) | 1989-02-15 | 2000-12-11 | 武田薬品工業株式会社 | 三環式縮合ピリミジン誘導体 |
| JPH04133055A (ja) | 1990-09-25 | 1992-05-07 | Konica Corp | 色再現性の改良されたハロゲン化銀カラー写真感光材料 |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| FR2733749B1 (fr) | 1995-05-05 | 1997-06-13 | Oreal | Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| US6472416B1 (en) | 1999-08-27 | 2002-10-29 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors |
| UA72611C2 (uk) | 2000-05-17 | 2005-03-15 | Орто-Макнейл Фармацевтикал, Інк. | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази |
| SK6862003A3 (en) | 2000-12-06 | 2004-02-03 | Aventis Pharma Gmbh | Guanidine and amidine derivatives as factor XA inhibitors, process for the preparation thereof, pharmaceutical composition and use thereof |
| WO2002072585A2 (de) * | 2001-03-14 | 2002-09-19 | Grünenthal GmbH | Substituierte pyrazolo- und thiazolopyrimidine als analgetika |
| WO2003091259A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| DE10221100C1 (de) | 2002-05-03 | 2003-06-05 | Neuhaus Elektronik Gmbh | Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung |
| JP2003327860A (ja) | 2002-05-09 | 2003-11-19 | Konica Minolta Holdings Inc | 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法 |
| ES2297217T3 (es) | 2002-06-19 | 2008-05-01 | Janssen Pharmaceutica Nv | Derivados sustituidos de 2,4-dihidro-pirrolo(3,4-b)quinolin-9-ona utilizados como inhibidores de fosfodiesterasa. |
| US7514441B2 (en) | 2002-08-26 | 2009-04-07 | Takeda Pharmaceutical Company Limited | Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents |
| ZA200500782B (en) * | 2002-08-26 | 2007-10-31 | Takeda Pharmaceutical | Calcium receptor modulating compound and use thereof |
| WO2004037159A2 (en) | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
| SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| US7329680B2 (en) | 2003-04-30 | 2008-02-12 | The Institute For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids |
| ES2290743T3 (es) | 2003-04-30 | 2008-02-16 | The Institutes For Pharmaceutical Discovery, Llc | Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas. |
| WO2004111193A2 (en) | 2003-06-12 | 2004-12-23 | Merck & Co., Inc. | Prodrugs of mitotic kinesin inhibitors |
| US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| JP2007530417A (ja) | 2003-07-01 | 2007-11-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 細胞及び生物の寿命及びストレス応答を操作するための組成物 |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| FR2865208B1 (fr) | 2004-01-16 | 2009-01-16 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique |
| US7279232B2 (en) | 2004-01-26 | 2007-10-09 | Universal Display Corporation | Electroluminescent stability |
| WO2005087765A1 (en) | 2004-03-04 | 2005-09-22 | Arena Pharmaceuticals, Inc. | Ligands of follicle stimulating hormone receptor and methods of use thereof |
| MXPA06012705A (es) | 2004-05-04 | 2007-03-26 | Acadia Pharm Inc | Compuestos con actividad en receptor de estrogeno. |
| US7825265B2 (en) | 2004-05-04 | 2010-11-02 | Acadia Pharmaceuticals Inc. | Compounds with activity at estrogen receptors |
| SG156637A1 (en) | 2004-10-12 | 2009-11-26 | Decode Genetics Ehf | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
| JP2008520692A (ja) | 2004-11-18 | 2008-06-19 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環置換カルボン酸 |
| JPWO2006057448A1 (ja) | 2004-11-26 | 2008-06-05 | 武田薬品工業株式会社 | アリールアルカン酸誘導体 |
| EP1841415A2 (en) | 2005-01-20 | 2007-10-10 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| CA2610854A1 (en) | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| WO2006129583A1 (ja) | 2005-05-30 | 2006-12-07 | Genecare Research Institute Co., Ltd. | ピラゾロン誘導体 |
| EP1900728A1 (en) | 2005-05-30 | 2008-03-19 | Genecare Research Institute Co., Ltd | Pharmaceutical composition comprising pyrazolone derivative |
| US20090170907A1 (en) | 2005-06-06 | 2009-07-02 | Smithkline Beecham Corporation | Chemical Compounds |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| US20090042856A1 (en) | 2005-09-01 | 2009-02-12 | Astellas Pharma Inc | Pyridazinone derivatives used for the treatment of pain |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| JP5498703B2 (ja) | 2006-01-23 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド |
| JPWO2007102531A1 (ja) | 2006-03-08 | 2009-07-23 | 武田薬品工業株式会社 | 併用薬 |
| EP2013206A1 (en) | 2006-04-25 | 2009-01-14 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2007139795A1 (en) | 2006-05-23 | 2007-12-06 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| EP2027116A2 (en) | 2006-05-23 | 2009-02-25 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| JP2009539881A (ja) | 2006-06-09 | 2009-11-19 | アイコス コーポレイション | Ｄｐ−２アンタゴニストとしての置換フェニル酢酸 |
| EP2044056B1 (en) | 2006-07-14 | 2012-08-22 | Novartis AG | Pyrimidine derivatives as alk-5 inhibitors |
| AR063680A1 (es) * | 2006-08-04 | 2009-02-11 | Merz Pharma Gmbh & Co Kgaa | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. |
| WO2008033894A2 (en) | 2006-09-14 | 2008-03-20 | Acadia Pharmaceuticals Inc. | Compounds with activity at estrogen receptors |
| EP2099454A4 (en) | 2006-11-17 | 2010-11-10 | Abbott Lab | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| WO2008097538A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
| EP2009002A1 (en) | 2007-06-21 | 2008-12-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems |
| US8188083B2 (en) | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| US8022209B2 (en) | 2007-09-12 | 2011-09-20 | Janssen Pharmaceutica Nv | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2009064274A1 (en) * | 2007-11-15 | 2009-05-22 | Eisai R & D Management Co., Ltd. | Enantiomerically enriched imidazoazepinone compounds |
| EP2280766A1 (en) * | 2007-12-11 | 2011-02-09 | CytoPathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| PT2231642E (pt) | 2008-01-11 | 2014-03-12 | Novartis Ag | Pirimidinas como inibidores de quinase |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| WO2010051048A1 (en) | 2008-02-20 | 2010-05-06 | The Wistar Institute | Microrna modulators and method for identifying and using the same |
| US20120010177A1 (en) | 2008-02-20 | 2012-01-12 | The Wistar Institute / North Carolina State University | MicroRNA Modulators and Method for Identifying And Using The Same |
| US20110003849A1 (en) | 2008-03-04 | 2011-01-06 | Hong Shen | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| WO2009148961A2 (en) | 2008-05-29 | 2009-12-10 | Wisconsin Alumni Research Foundation | Drugs to prevent hpv infection |
| CA2727245A1 (en) | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as inhibitors of faah |
| EP2299824B1 (en) | 2008-06-11 | 2013-06-19 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of faah |
| JP2011524894A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| EP2307377A1 (en) | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| ES2389478T3 (es) | 2008-06-25 | 2012-10-26 | Bristol-Myers Squibb Company | Derivados de dicetopiperidina como inhibidores de la fijación del VIH |
| US8263642B2 (en) | 2008-06-25 | 2012-09-11 | Vanderbilt University | Antimicrobial compounds and methods of use thereof |
| EP2303876B1 (en) | 2008-06-25 | 2014-03-19 | Bristol-Myers Squibb Company | Diketo azolopiperidines and azolopiperazines as anti-hiv agents |
| TWI461423B (zh) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
| CA2731323A1 (en) | 2008-07-28 | 2010-02-04 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
| MX2011001313A (es) | 2008-08-04 | 2011-03-04 | Merck Sharp & Dohme | Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos. |
| WO2010019392A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Purine derivatives for treatment of alzheimer's disease |
| MX2011002060A (es) | 2008-08-25 | 2011-04-05 | Irm Llc | Moduladores de la senda de hedgehog. |
| US8853125B2 (en) | 2008-09-24 | 2014-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| WO2010096115A1 (en) * | 2008-10-29 | 2010-08-26 | Apath, Llc | Compounds, compositions and methods for control of hepatitis c viral infections |
| EP2352725A1 (en) | 2008-11-07 | 2011-08-10 | Wyeth LLC | Quinoxaline-based lxr modulators |
| CA2749114C (en) | 2009-01-19 | 2013-12-17 | Daiichi Sankyo Company, Limited | Heteroatom-containing cyclic compound |
| WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| LT2403499T (lt) | 2009-03-02 | 2020-01-10 | Stemsynergy Therapeutics, Inc. | Būdai ir kompozicijos, skirti panaudoti vėžio gydymui ir wnt sąlygotų poveikių ląstelėje sumažinimui |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20120141483A1 (en) | 2009-06-04 | 2012-06-07 | Mary Katherine Delmedico | Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives |
| US20110021531A1 (en) | 2009-07-27 | 2011-01-27 | Chobanian Harry | Oxazole derivatives useful as inhibitors of faah |
| WO2011025706A2 (en) | 2009-08-26 | 2011-03-03 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| EP2501696B1 (en) | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| TWI531571B (zh) | 2009-11-06 | 2016-05-01 | 維它藥物公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物 |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011072064A1 (en) | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors |
| FR2953837B1 (fr) | 2009-12-10 | 2012-03-09 | Sanofi Aventis | Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique |
| WO2011079000A1 (en) | 2009-12-22 | 2011-06-30 | Schering Corporation | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF |
| WO2011088192A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| AU2011209754A1 (en) | 2010-01-28 | 2012-07-26 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions for the treatment of pain and other indicatons |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| US9290507B2 (en) | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| EP2371219A1 (en) | 2010-04-01 | 2011-10-05 | Basf Se | Herbicidal acylhydrazides |
| EP2555768B1 (en) | 2010-04-05 | 2018-08-29 | Fosun Orinove Pharmatech, Inc. | Ire-1 inhibitors |
| CA2794724A1 (en) | 2010-04-22 | 2011-10-27 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as modulators of faah |
| EP2560657B1 (en) | 2010-04-23 | 2015-09-16 | Kineta, Inc. | Diarylpyridine anti-viral compounds |
| EP2401915A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
| CN102048738A (zh) | 2010-12-08 | 2011-05-11 | 辽宁利锋科技开发有限公司 | 含有环嘧耐平药用复合物的药物组合物制剂 |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| KR20200088518A (ko) | 2011-07-29 | 2020-07-22 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 |
| JP2013159564A (ja) | 2012-02-02 | 2013-08-19 | Kowa Co | ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤 |
| DK2814829T3 (en) | 2012-02-13 | 2017-03-20 | Bristol Myers Squibb Co | RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| JP6225178B2 (ja) | 2012-05-31 | 2017-11-01 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体 |
-
2013
- 2013-05-30 JO JOP/2013/0166A patent/JO3407B1/ar active
- 2013-05-31 ES ES13729184T patent/ES2709119T3/es active Active
- 2013-05-31 RU RU2018146532A patent/RU2733959C2/ru active
- 2013-05-31 PL PL13729184T patent/PL2855476T3/pl unknown
- 2013-05-31 WO PCT/US2013/043679 patent/WO2013181579A2/en not_active Ceased
- 2013-05-31 SM SM20180626T patent/SMT201800626T1/it unknown
- 2013-05-31 JP JP2015515255A patent/JP6285918B2/ja active Active
- 2013-05-31 CA CA2874445A patent/CA2874445C/en active Active
- 2013-05-31 SG SG11201407890VA patent/SG11201407890VA/en unknown
- 2013-05-31 SI SI201331250T patent/SI2855476T1/sl unknown
- 2013-05-31 KR KR1020147036457A patent/KR102268155B1/ko active Active
- 2013-05-31 MX MX2014014497A patent/MX368455B/es active IP Right Grant
- 2013-05-31 LT LTEP13729184.5T patent/LT2855476T/lt unknown
- 2013-05-31 AR ARP130101930 patent/AR091236A1/es active IP Right Grant
- 2013-05-31 PE PE2014002228A patent/PE20150220A1/es active IP Right Grant
- 2013-05-31 AU AU2013267204A patent/AU2013267204B8/en active Active
- 2013-05-31 NZ NZ703459A patent/NZ703459A/en unknown
- 2013-05-31 MY MYPI2014003335A patent/MY172926A/en unknown
- 2013-05-31 PE PE2019000725A patent/PE20190973A1/es unknown
- 2013-05-31 RU RU2014154397A patent/RU2677291C2/ru active
- 2013-05-31 HU HUE13729184A patent/HUE040562T2/hu unknown
- 2013-05-31 BR BR112014030060-7A patent/BR112014030060B1/pt active IP Right Grant
- 2013-05-31 KR KR1020217018651A patent/KR102403007B1/ko active Active
- 2013-05-31 HR HRP20181889TT patent/HRP20181889T1/hr unknown
- 2013-05-31 DK DK13729184.5T patent/DK2855476T3/en active
- 2013-05-31 US US13/907,202 patent/US9126999B2/en active Active
- 2013-05-31 EP EP13729184.5A patent/EP2855476B1/en active Active
- 2013-05-31 UA UAA201414189A patent/UA113440C2/uk unknown
- 2013-05-31 PT PT13729184T patent/PT2855476T/pt unknown
- 2013-05-31 CN CN201380040379.2A patent/CN104507939B/zh active Active
- 2013-05-31 RS RS20181439A patent/RS57977B1/sr unknown
- 2013-05-31 IL IL268013A patent/IL268013B2/en unknown
- 2013-05-31 TW TW102119529A patent/TWI572606B/zh active
- 2013-05-31 CN CN201710514118.XA patent/CN107344941B/zh active Active
-
2014
- 2014-11-28 PH PH12014502660A patent/PH12014502660B1/en unknown
- 2014-11-28 CL CL2014003278A patent/CL2014003278A1/es unknown
- 2014-11-30 IL IL23598614A patent/IL235986B/en active IP Right Grant
- 2014-12-17 ZA ZA2014/09273A patent/ZA201409273B/en unknown
-
2015
- 2015-07-22 US US14/806,174 patent/US9446046B2/en active Active
-
2016
- 2016-08-10 US US15/233,520 patent/US9850242B2/en active Active
-
2017
- 2017-07-05 AU AU2017204586A patent/AU2017204586B2/en active Active
- 2017-12-14 US US15/841,767 patent/US10640500B2/en active Active
-
2018
- 2018-02-02 JP JP2018017637A patent/JP6619829B2/ja active Active
- 2018-11-29 CY CY20181101275T patent/CY1122692T1/el unknown
-
2019
- 2019-03-11 PH PH12019500522A patent/PH12019500522A1/en unknown
-
2020
- 2020-04-10 US US16/845,594 patent/US11130758B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091236A1 (es) | Compuestos de tetrahidropirazolopirimidina | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| ES2615742T3 (es) | Benzamidas sustituidas con actividad hacia receptores EP4 | |
| PE20160126A1 (es) | Derivados del bipirazol como inhibidores jak | |
| AR091939A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| UY31950A (es) | Inhibidores de ciclopropil-polimerasa | |
| ME02210B (me) | Derivati pirolotriazinona kao pi3k inhibitori | |
| EA201591429A1 (ru) | 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена | |
| AR091176A1 (es) | Pirrodilina-2-carboxamidas sustituidas | |
| AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR092073A1 (es) | Inhibidores de neprilisina | |
| JP2013531029A5 (es) | ||
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| EA201101297A1 (ru) | Аддитивные соли аминов, содержащих гидроксильные и/или карбоксильные группы, с производными аминоникотиновой кислоты в качестве ингибиторов dhodh | |
| AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| MEP12608A (en) | Derivatives of n-[phenyl (pyrrolidine-2-yl) methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |